Last update July 7, 2023

C15 H25 N3 O

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

A prodrug that is metabolized directly in the intestine to dextroamphetamine. It is used to treat Attention Deficit Hyperactivity Disorder (ADHD) and bulimia. Dextroamfetamine is a sympathomimetic drug, central nervous system stimulant, whose action and uses are similar to amphetamine (see information) which is its dextro isomer. Oral administration.

Dextroamfetamine is excreted in breast milk, concentrating about 3 times more than in plasma. This concentration assumes a relative dose about 6% (Ilett, 2007)

In infants whose mothers were taking dexamfetamine as treatment for ADHD, levels ranging from undetectable to 14% of maternal plasma levels have been measured and no problems were observed in the clinical follow-up of these infants. (Ilett, 2007)

There is little information on the impact of amphetamine abuse on the development and health of infants (Oei, 2012, Wise, 2007; Moretti, 2000), but it is known that they are more exposed to social problems, domestic violence, and lower breastfeeding rates. (Oei, 2010)

There is controversy over the possibly mild negative effect of amphetamine on prolactin (Petraglia, 1987; DeLeo, 1983), but milk production in mothers who took it therapeutically was not affected. (Öhman, 2015)

During breastfeeding, the therapeutic use (narcolepsy, ADHD) of dexamphetamine can be assessed, using the lowest possible effective dose and monitoring the occurrence of irritability, insomnia, lack of appetite and weight loss. Some authors contraindicate it. (Ornoy 2018)

Its use as an illegal drug is totally discouraged. (Oei, 2012). 

To minimize the risk, after the last recreational use of amphetamine, it is advisable to wait 55 hours (5 T ½, which eliminates 97% of the substance) before breastfeeding again. Meanwhile, express and discard milk from the breast regularly to maintain production.


See below the information of these related products:

  • Amfetamine (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Dexamfetamine Sulfate (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Narcolepsy. Narkolepsy. (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

  • Dexamfetamine Sulfate (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Methylphenidate (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

C15 H25 N3 O is Lisdexamfetamine Mesilate in Molecular formula.

Is written in other languages:

C15 H25 N3 O is also known as

Groups

C15 H25 N3 O belongs to these groups or families:

Tradenames

Main tradenames from several countries containing C15 H25 N3 O in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 96 %
Molecular weight 456 daltons
Protein Binding 16 - 20 %
VD 3.2 - 5.6 l/Kg
pKa 15.89 -
Tmax 3.5 - 4.7 hours
6.8 - 11 hours
M/P ratio 3.3 (2.2 - 4.8) -
Theoretical Dose 0.02 (0.01 - 0.04) mg/Kg/d
Relative Dose 5.7 (4 - 10.6) %

References

  1. Ornoy A. Pharmacological Treatment of Attention Deficit Hyperactivity Disorder During Pregnancy and Lactation. Pharm Res. 2018 Abstract
  2. AEMPS. Lisdexanfetamina. Ficha técnica. 2016 Full text (in our servers)
  3. Öhman I, Wikner BN, Beck O, Sarman I. Narcolepsy Treated with Racemic Amphetamine during Pregnancy and Breastfeeding. J Hum Lact. 2015 Abstract
  4. Shire. Lisdexamfetamine. Drug Summary. 2013 Full text (in our servers)
  5. Oei JL, Kingsbury A, Dhawan A, Burns L, Feller JM, Clews S, Falconer J, Abdel-Latif ME. Amphetamines, the pregnant woman and her children: a review. J Perinatol. 2012 Oct;32(10):737-47. Abstract Full text (link to original source) Full text (in our servers)
  6. Oei J, Abdel-Latif ME, Clark R, Craig F, Lui K. Short-term outcomes of mothers and infants exposed to antenatal amphetamines. Arch Dis Child Fetal Neonatal Ed. 2010 Jan;95(1):F36-41. Abstract
  7. Ilett KF, Hackett LP, Kristensen JH, Kohan R. Transfer of dexamphetamine into breast milk during treatment for attention deficit hyperactivity disorder. Br J Clin Pharmacol. 2007 Abstract
  8. Wise MS, Arand DL, Auger RR, Brooks SN, Watson NF; American Academy of Sleep Medicine. Treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007 Abstract Full text (link to original source) Full text (in our servers)
  9. Moretti ME, Lee A, Ito S. Which drugs are contraindicated during breastfeeding? Practice guidelines. Can Fam Physician. 2000 Sep;46:1753-7. Review. Abstract Full text (link to original source) Full text (in our servers)
  10. Petraglia F, De Leo V, Sardelli S, Mazzullo G, Gioffrè WR, Genazzani AR, D'Antona N. Prolactin changes after administration of agonist and antagonist dopaminergic drugs in puerperal women. Gynecol Obstet Invest. 1987;23(2):103-9. Abstract
  11. DeLeo V, Cella SG, Camanni F, Genazzani AR, Müller EE. Prolactin lowering effect of amphetamine in normoprolactinemic subjects and in physiological and pathological hyperprolactinemia. Horm Metab Res. 1983 Sep;15(9):439-43. Abstract

Total visits

1,356

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM